Survodutide indirect comparison versus semaglutide and tirzeparatide

Survodutide Indirect Comparison Versus Semaglutide and Tirzepatide

Introduction

Survodutide is a novel dual agonist targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), representing a new frontier in the pharmacotherapy of obesity and type 2 diabetes (T2D). Semaglutide (a selective GLP-1R agonist) and tirzepatide (a dual GLP-1R/glucose-dependent insulinotropic polypeptide [GIPR] agonist) are established therapies with proven efficacy in weight reduction and glycemic control. This summary synthesizes available clinical data from randomized controlled trials (RCTs), indirect treatment comparisons, and meta-analyses to provide an in-depth scientific discussion of the relative efficacy and safety of survodutide in comparison with semaglutide and tirzepatide.

Comparative Efficacy: Glycemic Control

Survodutide vs. Semaglutide

A pivotal phase II, randomized trial evaluated multiple weekly or twice-weekly doses of survodutide (up to 3.6 mg total/week) against placebo and open-label semaglutide (1.0 mg/week) in people with T2D on a stable metformin background. After 16 weeks, survodutide showed dose-dependent reductions in HbA1c:

  • Semaglutide 1.0 mg: Mean HbA1c change –16.07 mmol/mol (–1.47%)
  • Survodutide 1.8 mg biweekly: Mean change –18.38 mmol/mol (–1.68%)
  • Survodutide 1.8 mg weekly: Mean change –18.72 mmol/mol (–1.71%)

Notably, low-dose survodutide (0.9 mg/week) achieved similar HbA1c reductions to semaglutide (–15.95 mmol/mol versus –16.07 mmol/mol; both ~–1.46%) (Blüher, 2023). These results suggest at least equivalent glycemic control at lower doses and potentially greater efficacy at higher doses, although the duration of observation was short (16 weeks).

Survodutide vs. Tirzepatide

There is no direct or indirect trial directly comparing survodutide and tirzepatide. However, tirzepatide’s efficacy, as reported in the SURPASS-2 trial, resulted in HbA1c reductions up to –2.30% for a 15 mg dose, superior to semaglutide 1 mg (–1.86%), over 40 weeks (Frías et al., 2021; referenced in multiple meta-analyses). This implies that tirzepatide has a more pronounced glucose-lowering effect than semaglutide, and thus likely exceeds that of survodutide at the doses and durations studied thus far, although cross-trial comparisons are limited by differences in study design, baseline characteristics, and duration.

Comparative Efficacy: Weight Reduction

Survodutide vs. Semaglutide

In the aforementioned phase II study (Blüher, 2023):

  • Semaglutide 1.0 mg: Mean bodyweight change –5.3% (95% CI: –6.6 to –4.1)
  • Survodutide (≥1.8 mg/week): Up to –8.7% (95% CI: –10.1 to –7.3) reduction

Survodutide at higher doses (>1.8 mg weekly or biweekly) outperformed semaglutide 1.0 mg for absolute and relative weight reduction at 16 weeks. The proportion of participants achieving ≥5% and ≥10% weight loss was higher in the highest-dose survodutide groups than in the semaglutide group.

Meta-analyses confirm that survodutide’s weight loss potential surpasses semaglutide at lower doses, with dose-dependent efficacy (Sinha, 2025).

Survodutide vs. Tirzepatide

Direct comparison data are lacking; however, RCTs for tirzepatide demonstrate:

  • Tirzepatide 15 mg: Mean weight loss (obesity + T2D, 72 weeks): –15% up to –20.9% in some studies (Garvey et al., 2023).
  • Semaglutide 2.4 mg: –10% to –15% in parallel patient groups at similar durations (Davies et al., 2021).

A recent overview indicates survodutide achieves up to 18.7% weight loss in certain phase II programs, while tirzepatide reaches ~20% in phase III trials for severe obesity without T2D (Jyothi, 2025). Hence, survodutide appears to approach but not exceed the maximal weight loss observed with tirzepatide at this time.

A Bayesian network meta-analysis encompassing GLP-1RAs, dual agonists, and triple agonists corroborates that dual agonists (like tirzepatide and survodutide) achieve greater mean weight loss (–11.0 kg) than GLP-1 RAs alone (–9.0 kg), and that retatrutide (a triple agonist) may offer incremental benefit at the expense of more adverse events (Sinha, 2025).

Cardiometabolic and Hepatic Benefits

Advanced analyses show that survodutide, by engaging both GLP-1R and GCGR, not only enhances weight reduction but also drives reductions in hepatic steatosis, fibrosis, and systemic inflammation, with promising implications for metabolic dysfunction-associated steatohepatitis (MASH) and cardio-renal-metabolic protection (Jyothi, 2025). While tirzepatide and semaglutide also improve metabolic profiles, dual agonism may confer broader hepatic benefits.

Safety and Tolerability

Adverse Event Profiles

  • Survodutide: GI adverse events (nausea, vomiting) are frequent—reported in up to 77.8% at higher doses, leading to discontinuation in 15.9% (especially pronounced during rapid dose escalation) (Blüher, 2023).
  • Semaglutide: GI AEs occur in 52.0%, with discontinuation for AEs at 4.0%.
  • Tirzepatide: GI AEs and discontinuation rates generally similar or slightly higher than semaglutide at higher doses (Frías et al., 2021); pooled analysis shows no significant increased risk of serious AEs or hypoglycemia compared to semaglutide (Rodriguez et al., 2024).

A meta-analysis notes no meaningful difference in GI AE rates between survodutide and placebo, though with wide confidence intervals (Alhamad et al., 2024). However, rates appear higher compared to semaglutide and tirzepatide in head-to-head reporting, emphasizing the need for slower up-titration and patient selection.

Mild increases in heart rate are observed with all agents (survodutide, semaglutide, tirzepatide), but clinical significance remains to be fully characterized.

Limitations and Future Directions

  • The survodutide phase II trial compared its efficacy to semaglutide 1.0 mg/week, which is lower than the 2.4 mg/week dose used for obesity. This limits the robustness of indirect comparisons to tirzepatide and higher-dose semaglutide.
  • Data beyond 16 weeks for survodutide are pending; ongoing phase III SYNCHRONIZE and CVOT outcome trials will provide definitive head-to-head and outcomes data.
  • No published studies directly compare survodutide to tirzepatide; all insights are extrapolated from cross-study ± meta-analytic data.

Conclusions

  • Weight Reduction: Both survodutide and tirzepatide clearly exceed semaglutide (GLP-1 mono-agonist) in mean weight loss. The difference between survodutide and tirzepatide is likely small, with tirzepatide potentially showing slightly superior efficacy at the highest studied doses and durations.
  • Glycemic Control: Tirzepatide demonstrates the greatest HbA1c reduction, followed by survodutide and semaglutide, though all are effective.
  • Safety: Survodutide may be associated with higher rates of GI adverse events and discontinuation than semaglutide or tirzepatide, a risk that could be mitigated by slower titration.
  • Broader Benefits: Survodutide may offer unique hepato- and cardiometabolic benefits yet to be fully elucidated, with ongoing trials positioned to clarify these effects.

Given the available evidence, survodutide is a highly promising addition to the incretin-based therapeutic class, offering superior weight loss to semaglutide 1.0 mg, comparable glycemic efficacy, and unique mechanistic advantages. Compared to tirzepatide, efficacy is at least comparable, but confirmation awaits direct comparative data and longer-term outcomes.

References

For insights on tirzepatide and semaglutide head-to-head:
- Rodriguez, P. J. et al. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med.
- Lilly's tirzepatide superior to Wegovy® (semaglutide) in head‐to‐head trial showing an average weight loss of 20.2% vs. 13.7%

REFERENCES

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison - PMC - last accessed: 2025-10-08

Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity - PMC - last accessed: 2025-10-08

Tirzepatide vs semaglutide: A head-to-head comparison for management of obesity - Healthed - last accessed: 2025-10-08

Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials - PMC - last accessed: 2025-10-08

Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial - PMC - last accessed: 2025-10-08

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials - PubMed - last accessed: 2025-10-08